Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma

Ryuichi Kanai, Hideyuki Tomita, Yuichi Hirose, Shigeo Oba, Steven Goldman, Hideyuki Okano, Takeshi Kawase, Takahito Yazaki

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Although second-generation replication-conditional herpes simples virus type 1 (HSV-1) vectors defective for both ribonucleotide reductase (RR) and the virulence factor γ134.5 have been proven safe through a number of animal experiments and clinical trials, their therapeutic efficacy was also markedly reduced. To overcome this situation, we concentrated on the use of a tumor-specific promoter in this study, to express ICP34.5 selectively in malignant glioma cells. As a molecular marker for malignant glioma, we focused on the neural RNA-binding protein, Musashi1. On the basis of the results of defective vector dvM345, as reported previously, we created, via homologous recombination, a novel HSV-1 vector termed KeM34.5, which expresses ICP34.5 under the transcriptional control of the musashi1 gene promoter (P/musashi1). Cytotoxicity mediated by KeM34.5 was significantly enhanced in human glioma cell lines (U87MG, U87MG-E6, U251, and T98G), resulting in an approximately 2-log increase in viral yield, compared with its parental vector G207. This virus also showed much higher therapeutic efficacy in the in vivo glioma model, while maintaining the desirable neuroattenuated phenotype. These results suggest that oncolytic HSV-1 expressing ICP34.5 under the transcriptional control of the musashi1 gene promoter could be a promising therapeutic agent for the treatment of malignant glioma.

Original languageEnglish
Pages (from-to)63-73
Number of pages11
JournalHuman Gene Therapy
Volume18
Issue number1
DOIs
Publication statusPublished - 01-01-2007

Fingerprint

Oncolytic Viruses
Human Herpesvirus 1
Glioma
Viruses
Therapeutics
Ribonucleotide Reductases
RNA-Binding Proteins
Homologous Recombination
Virulence Factors
Carcinogens
Genes
Clinical Trials
Phenotype
Cell Line

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

@article{321bc555f8e4475eb4fb7c52e58fc2a5,
title = "Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma",
abstract = "Although second-generation replication-conditional herpes simples virus type 1 (HSV-1) vectors defective for both ribonucleotide reductase (RR) and the virulence factor γ134.5 have been proven safe through a number of animal experiments and clinical trials, their therapeutic efficacy was also markedly reduced. To overcome this situation, we concentrated on the use of a tumor-specific promoter in this study, to express ICP34.5 selectively in malignant glioma cells. As a molecular marker for malignant glioma, we focused on the neural RNA-binding protein, Musashi1. On the basis of the results of defective vector dvM345, as reported previously, we created, via homologous recombination, a novel HSV-1 vector termed KeM34.5, which expresses ICP34.5 under the transcriptional control of the musashi1 gene promoter (P/musashi1). Cytotoxicity mediated by KeM34.5 was significantly enhanced in human glioma cell lines (U87MG, U87MG-E6, U251, and T98G), resulting in an approximately 2-log increase in viral yield, compared with its parental vector G207. This virus also showed much higher therapeutic efficacy in the in vivo glioma model, while maintaining the desirable neuroattenuated phenotype. These results suggest that oncolytic HSV-1 expressing ICP34.5 under the transcriptional control of the musashi1 gene promoter could be a promising therapeutic agent for the treatment of malignant glioma.",
author = "Ryuichi Kanai and Hideyuki Tomita and Yuichi Hirose and Shigeo Oba and Steven Goldman and Hideyuki Okano and Takeshi Kawase and Takahito Yazaki",
year = "2007",
month = "1",
day = "1",
doi = "10.1089/hum.2006.107",
language = "English",
volume = "18",
pages = "63--73",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma. / Kanai, Ryuichi; Tomita, Hideyuki; Hirose, Yuichi; Oba, Shigeo; Goldman, Steven; Okano, Hideyuki; Kawase, Takeshi; Yazaki, Takahito.

In: Human Gene Therapy, Vol. 18, No. 1, 01.01.2007, p. 63-73.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma

AU - Kanai, Ryuichi

AU - Tomita, Hideyuki

AU - Hirose, Yuichi

AU - Oba, Shigeo

AU - Goldman, Steven

AU - Okano, Hideyuki

AU - Kawase, Takeshi

AU - Yazaki, Takahito

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Although second-generation replication-conditional herpes simples virus type 1 (HSV-1) vectors defective for both ribonucleotide reductase (RR) and the virulence factor γ134.5 have been proven safe through a number of animal experiments and clinical trials, their therapeutic efficacy was also markedly reduced. To overcome this situation, we concentrated on the use of a tumor-specific promoter in this study, to express ICP34.5 selectively in malignant glioma cells. As a molecular marker for malignant glioma, we focused on the neural RNA-binding protein, Musashi1. On the basis of the results of defective vector dvM345, as reported previously, we created, via homologous recombination, a novel HSV-1 vector termed KeM34.5, which expresses ICP34.5 under the transcriptional control of the musashi1 gene promoter (P/musashi1). Cytotoxicity mediated by KeM34.5 was significantly enhanced in human glioma cell lines (U87MG, U87MG-E6, U251, and T98G), resulting in an approximately 2-log increase in viral yield, compared with its parental vector G207. This virus also showed much higher therapeutic efficacy in the in vivo glioma model, while maintaining the desirable neuroattenuated phenotype. These results suggest that oncolytic HSV-1 expressing ICP34.5 under the transcriptional control of the musashi1 gene promoter could be a promising therapeutic agent for the treatment of malignant glioma.

AB - Although second-generation replication-conditional herpes simples virus type 1 (HSV-1) vectors defective for both ribonucleotide reductase (RR) and the virulence factor γ134.5 have been proven safe through a number of animal experiments and clinical trials, their therapeutic efficacy was also markedly reduced. To overcome this situation, we concentrated on the use of a tumor-specific promoter in this study, to express ICP34.5 selectively in malignant glioma cells. As a molecular marker for malignant glioma, we focused on the neural RNA-binding protein, Musashi1. On the basis of the results of defective vector dvM345, as reported previously, we created, via homologous recombination, a novel HSV-1 vector termed KeM34.5, which expresses ICP34.5 under the transcriptional control of the musashi1 gene promoter (P/musashi1). Cytotoxicity mediated by KeM34.5 was significantly enhanced in human glioma cell lines (U87MG, U87MG-E6, U251, and T98G), resulting in an approximately 2-log increase in viral yield, compared with its parental vector G207. This virus also showed much higher therapeutic efficacy in the in vivo glioma model, while maintaining the desirable neuroattenuated phenotype. These results suggest that oncolytic HSV-1 expressing ICP34.5 under the transcriptional control of the musashi1 gene promoter could be a promising therapeutic agent for the treatment of malignant glioma.

UR - http://www.scopus.com/inward/record.url?scp=33846235518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846235518&partnerID=8YFLogxK

U2 - 10.1089/hum.2006.107

DO - 10.1089/hum.2006.107

M3 - Article

C2 - 17238803

AN - SCOPUS:33846235518

VL - 18

SP - 63

EP - 73

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 1

ER -